ImmuCell Corporation
NASDAQ:ICCC · NASDAQ Capital Market
+$0.19 today
Vol 0.03M · Avg 0.03M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.0M +51.8% | -$2.2M +62.6% | -$5.8M -131.6% | -$2.5M -3085.3% | -$78.3K | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $2.7M +1.6% | $2.7M -1.1% | $2.7M +9.2% | $2.5M +1.1% | $2.5M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $31.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $295.9K -9.2% | $326.0K -11.6% | $368.9K +38.5% | $266.2K +84.5% | $144.3K | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$2.1M -405.0% | -$406.5K +82.1% | -$2.3M -23.8% | -$1.8M -13.0% | -$1.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $352.1K +122.2% | -$1.6M -271.6% | -$426.8K -145.6% | $935.6K +204.3% | -$897.4K | $592.6M | $1.3B | $626.2M |
| Inventory | -$2.2M -408.2% | $699.2K +139.4% | -$1.8M +39.9% | -$2.9M -195.6% | -$997.5K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$195.3K -153.8% | $362.6K +131.0% | $157.0K +45856.8% | $342 -100.0% | $245.8M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$55.2K -147.0% | $117.4K +104.8% | -$2.4M -1448.5% | $179.9K +100.1% | -$245.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $2.5M +2871.2% | -$91.8K -135.2% | $260.8K +805.6% | $28.8K +55.2% | $18.6K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $2.5M +591.6% | $357.9K +107.7% | -$4.7M -202.8% | -$1.5M -261.8% | $954.2K | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.3M -168.5% | -$465.7K +75.4% | -$1.9M +52.4% | -$4.0M -52.4% | -$2.6M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 -100.0% | $11.0K -28.1% | $15.3K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 +100.0% | -$15.3K | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 -100.0% | $996.0K | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $36.1K +702.9% | $4.5K +81.9% | $2.5K -77.5% | $11.0K -28.1% | $15.3K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$1.2M -163.3% | -$461.2K +75.6% | -$1.9M +52.3% | -$4.0M -148.2% | -$1.6M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$1.5M -0.7% | -$1.5M -180.9% | $1.8M +64.5% | $1.1M +399.5% | -$368.3K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $349.3K -92.0% | $4.4M | $0 -100.0% | $30.7M +624.5% | $4.2M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$82.5K -1538.1% | -$5.0K +92.0% | -$62.8K -652.4% | $11.4K -18.6% | $14.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$1.2M -142.1% | $2.9M +64.6% | $1.8M +57.2% | $1.1M -71.3% | $3.9M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $48.6K -98.3% | $2.8M +157.8% | -$4.8M -9.5% | -$4.4M -235.8% | $3.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $1.2M +1236.0% | -$107.8K +98.4% | -$6.6M -19.0% | -$5.5M -233.6% | -$1.7M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Century Therapeutics, Inc.
NASDAQ:IPSC
$196.58M
Equillium, Inc.
NASDAQ:EQ
$107.81M
Fortress Biotech, Inc.
NASDAQ:FBIO
$100.49M
OS Therapies Incorporated
AMEX:OSTX
$81.06M
Cue Biopharma, Inc.
NASDAQ:CUE
$70.99M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$69.75M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$63.36M
Coeptis Therapeutics, Inc.
NASDAQ:COEP
$55.98M
Genenta Science S.p.A.
GNTA
$32.55M
Senti Biosciences, Inc.
SNTI
$24.58M
SEC Filings
Recent regulatory filings
No filings found.
Does ICCC generate free cash flow?
ImmuCell Corporation (ICCC) generated $1.22M of free cash flow in fiscal 2025.
How much operating cash flow does ICCC produce?
Operating cash flow was $2.48M, before capital expenditures of $1.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.